Lubiprostone
Who holds supplier records for Lubiprostone? 8 organisations hold a current record for Lubiprostone: an active US FDA Type II Drug Master File. A further 3 organisations have only historical (inactive) DMF filings. Recorded organisation countries for current records: India (4), Taiwan (1) and China (1); not recorded for 2.
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Lubiprostone: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/lubiprostone
Reading the evidence
- 8 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- Most recorded organisations are in India
4 of the 6 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.
- 4 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
- US product patents listed
The latest patent listed in the FDA Orange Book for an approved product containing Lubiprostone expires 25 Oct 2027. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.
Current records (8)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Lubiprostone. Country is the organisation's recorded country, not necessarily the manufacturing site.
- Apotex Pharmachem India Pvt. Ltd.IndiaActive DMF 31275 · latest filing Jan 2017
- Dr. Reddy's Laboratories Ltd.India Company GMP cert on recordActive DMF 24705 · latest filing Mar 2011
- EVERLIGHT CHEMICAL INDUSTRIAL CORPTaiwanActive DMF 23383 · latest filing Dec 2009
- MSN Laboratories Private LimitedIndia Company GMP cert on recordActive DMF 34416 · latest filing Dec 2019
- SUCAMPO PHARMA AMERICAS LLCActive DMF 18091 · latest filing Feb 2005
- Sun Pharmaceutical Industries LimitedIndia Company GMP cert on recordActive DMF 32472 · latest filing Mar 2018
- YS LIFE SCIENCE CO LTDActive DMF 37281 · latest filing Aug 2022
- Zhejiang Ausun Pharmaceutical Co., Ltd.China Company GMP cert on recordActive DMF 30802 · latest filing Aug 2016
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
Historical records (3)
Organisations whose Type II DMFs for Lubiprostone are no longer active. These show a past filing, not current supply.
Show all 3 historical records
- Italy · Inactive DMF 24286 · filed Nov 2010
- APOTEX PHARMACHEM INCInactive DMF 23490 · filed Jan 2010
- Teva Pharmaceutical Industries Ltd.Israel · Inactive DMF 23402 · filed Dec 2009
US product patents and exclusivity
The FDA Orange Book lists patents and exclusivities for specific approved products (14 listed products contain Lubiprostone). The latest listed patent expires 25 Oct 2027. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.
Overview
Lubiprostone is a chloride channel activator used in the treatment of chronic idiopathic constipation, opioid-induced constipation, and irritable bowel syndrome with constipation. It increases intestinal fluid secretion, thereby improving fecal transit.
Chemical identity
- IUPAC name
- 7-[(2R,4aR,5R,7aR)-2-(1,1-difluoropentyl)-2-hydroxy-6-oxo-3,4,4a,5,7,7a-hexahydrocyclopenta[b]pyran-5-yl]heptanoic acid
- Canonical SMILES
- CCCCC([C@]1(CC[C@H]2[C@H](O1)CC(=O)[C@@H]2CCCCCCC(=O)O)O)(F)F
- InChIKey
- WGFOBBZOWHGYQH-MXHNKVEKSA-N
- Synonyms
- Amitiza API, amitiza, lubiprostone hemiketal, ru-0211, spi-0211
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Chloride Channel Activator
- Mechanism of action
- Chloride Channel Activators
Therapeutic areas
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Lubiprostone?
8 organisations hold an active US FDA Type II Drug Master File or a CEP for Lubiprostone: Apotex Pharmachem India Pvt. Ltd. (India), Dr. Reddy's Laboratories Ltd. (India), EVERLIGHT CHEMICAL INDUSTRIAL CORP (Taiwan), MSN Laboratories Private Limited (India), SUCAMPO PHARMA AMERICAS LLC, Sun Pharmaceutical Industries Limited (India), YS LIFE SCIENCE CO LTD and Zhejiang Ausun Pharmaceutical Co., Ltd. (China). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Lubiprostone Drug Master Files are active?
Apotex Pharmachem India Pvt. Ltd. (DMF 31275), Dr. Reddy's Laboratories Ltd. (DMF 24705), EVERLIGHT CHEMICAL INDUSTRIAL CORP (DMF 23383), MSN Laboratories Private Limited (DMF 34416), SUCAMPO PHARMA AMERICAS LLC (DMF 18091), Sun Pharmaceutical Industries Limited (DMF 32472), YS LIFE SCIENCE CO LTD (DMF 37281) and Zhejiang Ausun Pharmaceutical Co., Ltd. (DMF 30802). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
What do the historical Lubiprostone records mean?
3 organisations have only inactive Type II DMFs for Lubiprostone. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.
Does the FDA Orange Book list patents for products containing Lubiprostone?
Yes. The latest patent listed for an approved US product containing Lubiprostone expires 25 Oct 2027, across 14 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.
How do I qualify a Lubiprostone supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Lubiprostone?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.